Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Inhibitors of the mutant isocitrate dehydrogenase 1 (IDH1) entered recently in clinical trials for glioma treatment. Mutant IDH1 produces high levels of 2-hydroxyglurate (2HG), thought to initiate oncogenesis through epigenetic modifications of gene expression. In this study, we show the initial evi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Main Authors: Andronesi, Ovidiu C., Arrillaga-Romany, Isabel C., Ly, K. Ina, Bogner, Wolfgang, Ratai, Eva M., Reitz, Kara, Iafrate, A. John, Dietrich, Jorg, Gerstner, Elizabeth R., Chi, Andrew S., Rosen, Bruce R., Wen, Patrick Y., Cahill, Daniel P., Batchelor, Tracy T.
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5902553/
https://ncbi.nlm.nih.gov/pubmed/29662077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-03905-6
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares